RFA
VRTX icon

Resurgent Financial Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Resurgent Financial Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,260
Closed -$563K – 335
2026
Q1 		$563K Buy
1,260
+111
+10% +$51.8K 0.2% 121
2025
Q4 		$521K Buy
+1,149
New +$495K 0.26% 111
2025
Q3 		– Sell
-607
Closed -$270K – 223
2025
Q2 		$270K Buy
607
+6
+1% +$2.77K 0.15% 153
2025
Q1 		$291K Buy
601
+15
+3% +$6.99K 0.18% 141
2024
Q4 		$236K Sell
586
-294
-33% -$136K 0.14% 157
2024
Q3 		$409K Sell
880
-19
-2% -$9.13K 0.24% 124
2024
Q2 		$421K Sell
899
-100
-10% -$43.4K 0.26% 116
2024
Q1 		$418K Buy
999
+189
+23% +$79.9K 0.22% 121
2023
Q4 		$330K Buy
810
+574
+243% +$212K 0.2% 124
2023
Q3 		$82.1K Buy
236
+17
+8% +$5.95K 0.06% 254
2023
Q2 		$77.1K Sell
219
-7
-3% -$2.36K 0.05% 270
2023
Q1 		$71.2K Sell
226
-473
-68% -$142K 0.05% 280
2022
Q4 		$202K Sell
699
-634
-48% -$193K 0.11% 201
2022
Q3 		$386K Buy
1,333
+72
+6% +$20.7K 0.26% 108
2022
Q2 		$355K Sell
1,261
-76
-6% -$20.3K 0.23% 118
2022
Q1 		$349K Buy
+1,337
New +$317K 0.22% 116

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Resurgent Financial Advisors's VRTX Position: Q2 2026 in Review

Resurgent Financial Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 1,260 shares — an estimated $563K sold.

Resurgent Financial Advisors first reported a position in VRTX in Q1 2022 and held it in 16 quarters. The position peaked at $563K in Q1 2026. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Resurgent Financial Advisors reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Resurgent Financial Advisors sold 1,260 Vertex Pharmaceuticals shares in Q2 2026, an estimated $563K.
  • Resurgent Financial Advisors first reported a position in Vertex Pharmaceuticals in Q1 2022 and held it in 16 quarters.
  • Resurgent Financial Advisors's Vertex Pharmaceuticals position peaked at $563K in Q1 2026.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Resurgent Financial Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.